- Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system
- Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allografting
- The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on their immune system
- The AditxtScore(TM) system is initially focused on providing customers with reports looking into their vulnerability and immune response to SARS-CoV-2 and its known variants
Every 9 minutes, a person is placed on an organ transplant waiting list in the United States. Yet, due to a critical shortage of organs, only 41,000 transplantations took place in 2021 (https://ibn.fm/gmVnu). In spite of a wide array of medical innovations in recent years, industry data suggest that approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years, highlighting the critical need for a practical and cost-effective solution to harmful immune responses. Aditxt (NASDAQ: ADTX) has sought to address this medical conundrum through the creation of immune reprogramming technologies which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases), and allergens.
While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s immune reprogramming platform, looks to address disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection and cancer. The technology, which utilizes…
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.